Interpreting discordance on dual-tracer positron emission tomography–computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma

Ashwini Kalshetty; Sandip Basu

doi:10.4103/wjnm.WJNM_15_20

World Journal of Nuclear Medicine, Table of Contents

CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(04): 414-416
DOI: 10.4103/wjnm.WJNM_15_20

Case Report

Interpreting discordance on dual-tracer positron emission tomography–computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma

Ashwini Kalshetty

¹Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe

²Homi Bhabha National Institute, Mumbai, Maharashtra, India

,

Sandip Basu

¹Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe

²Homi Bhabha National Institute, Mumbai, Maharashtra, India

› Author Affiliations

Abstract

Second primary malignancies (SPMs) are known to be associated with neuroendocrine tumors (NETs). The association necessitates a careful assessment of the dual-tracer positron emission tomography–computed tomography (PET-CT) imaging findings to identify these malignancies earlier. Such early diagnosis can provide incremental benefit for screening these SPMs apart from their known applications in the management of NETs. A case of incidentally detected metachronous triple-negative breast carcinoma on dual-tracer PET-CT imaging is presented using ¹⁸fluoro-2-deoxy-D-glucose (FDG) and ⁶⁸Ga-DOTATATE that showed a high uptake on FDG but no uptake on somatostatin receptor-based imaging.

Keywords

⁶⁸Ga-DOTATATE - dual-tracer positron emission tomography–computed tomography - fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography - metastatic neuroendocrine tumors - triple-negative breast carcinoma

Full Text

References

References
1 Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B, Talbot D, et al. Metachronous primary cancers in neuroendocrine tumour patients. EJEA 2017;52. p. 13. doi: 10.1530/endoabs.52.P13. Available from: https://doi.org/10.1530/endoabs. 52.P13. [Last accessed on 2020 Mar 21].
2 Kharmate G, Rajput PS, Lin YC, Kumar U. Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell Int 2013;13:93.
3 Basu S, Abhyankar A. The use of 99mTc-HYNIC-TOC and ¹⁸F-FDG PET/CT in the evaluation of duodenal neuroendocrine tumor with atypical and extensive metastasis responding dramatically to a single fraction of PRRT with 177Lu-DOTATATE. J Nucl Med Technol 2014;42:296-8.
4 Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmed 2008;47:261-5.
5 Dalm SU, Haeck J, Doeswijk GN, de Blois E, de Jong M, van Deurzen CH. SSTR-mediated imaging in breast cancer: Is there a role for radiolabeled somatostatin receptor antagonists? J Nucl Med 2017;58:1609-14.
6 Chereau E, Durand L, Frati A, Prignon A, Talbot JN, Rouzier R. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and ¹⁸F-FDG PET imaging in an animal model. Anticancer Res 2013;33:3015-9.